CSIMarket Company Name, Ticker, Suppliers, else..
 
Palvella Therapeutics Inc   (NASDAQ: PVLA)
 
Price: $152.5900 $2.62 1.747%
Day's High: $152.88999938964844 Week Perf: 2.93 %
Day's Low: $ 143.47 30 Day Perf: 9.75 %
Volume (M): 245,677 52 Wk High: $ 161.38
Volume (M$): $ 0 52 Wk Avg: $107.16
Open: $147.95 52 Wk Low: $50.82



 Market Capitalization (Millions $) 2,191
 Shares Outstanding (Millions) 14
 Employees 29
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -62
 Cash Flow (TTM) (Millions $) 136
 Capital Exp. (TTM) (Millions $) 0

Business Description


Palvella Therapeutics, Inc. is a biopharmaceutical company developing product candidates for rare skin diseases and vascular malformations. The company uses a proprietary drug development platform and is conducting clinical trials for QTORIN™ rapamycin and QTORIN™ pitavastatin. Palvella also oversees regulatory, manufacturing, and commercialization activities for its product candidates.


   Company Address: 353 W. Lancaster Ave Wayne 19087 PA
   Company Phone Number: 253-1461   Stock Exchange / Ticker: NASDAQ PVLA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARVN   -1.5%    
NKTR   -3.13%    
NRIX   -1.87%    
PFE        1.75% 
RYTM   -4.76%    
TEVA   -2.38%    
• View Complete Report
   



Product Service News

Revolutionizing Treatment for Venous Malformations Palvella Therapeutics Pioneers Rapamycin Advances in New R...

Published Wed, Sep 17 2025 12:40 PM UTC

In a groundbreaking press release, Palvella Therapeutics has announced significant progress in understanding the pathogenesis of venous malformations, also detailing the systemic off-label use of rapamycin as a targeted therapy. This announcement comes in the wake of research published in the prestigious journal Lymphatic Research and Biology , which highlights recent advan...
Product Service News

Expansion of Phase 3 SELVA Trial for QTORIN Rapamycin 3.9% Anhydrous Gel in Treating Microcystic Lymphatic Malformati...

Published Fri, Apr 11 2025 12:28 PM UTC

In an exciting development for pediatric dermatology, Palvella Therapeutics has announced that its investigational therapy, QTORIN Rapamycin 3.9% anhydrous gel, is making strides toward addressing microcystic lymphatic malformations (MLMs). This novel topical treatment was recently featured in an oral presentation by Dr. Amy Paller, M.S. M.D. Chair of Dermatology at Northwes...
Merger and Acquisition

Palvella Therapeutics Soars: Closing of Merger with Pieris Pharmaceuticals and $78.9 Million Placement Signals Bright Future for Rare Disease Solutions,

Published Fri, Dec 13 2024 7:55 PM UTC

Palvella Therapeutics: A New Dawn for Rare Disease BiopharmaceuticalsIn a significant development for the biopharmaceutical landscape, Palvella Therapeutics is poised to make its mark on the Nasdaq, debuting under the ticker symbol PVLA. This occasion heralds a pivotal moment not only for the company itself but for the realm of rare disease treatment, as Palvella advances it...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 10.1
PEG (TTM) -

Financial Strength Current
Quick Ratio 26.23
Working Capital Ratio 26.44
Leverage Ratio (MRQ) 0.17
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.88 $
Revenues (TTM) -
Cash Flow (TTM) 9.47 $
Cash 21.83 $
Book Value 15.11 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,127,448
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Palvella Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.